These include their overexpression in cancer tissues, presence in extracellular compartments, and involvement in ligand-receptor interactions—such as with RAGE and Toll-like receptor 4 (TLR4)—that can be disrupted by small molecules or monoclonal antibodies (1, 7). The gene discussed is TLR4; the disease is cancer.